secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106533
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date
----------------------------------------------------------------------------

- Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.
- Net income $2.4M ($0.19 diluted EPS) vs. net loss prior year; revenues $17.6M, down from $28.6M.
- FDA accepted tab-cel BLA with Priority Review; PDUFA goal date January 10, 2026.
- Completed transfer of substantially all tab-cel activities to Pierre Fabre; $40M milestone due on FDA approval.
- Full-year 2025 operating expenses expected to decrease at least 60% vs 2024; strategic options evaluation resumed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/0000950170-25-106533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer